What does nucynta ER AG — product revenues, net mean?

This metric represents the net revenue generated from the sale of the Nucynta ER product line, reflecting the total sales after accounting for returns, rebates, and other adjustments. It serves as a key indicator of the product's market adoption and commercial performance within the company's specialty pharmaceutical portfolio. Monitoring this revenue stream helps investors assess the product's contribution to overall top-line growth and its lifecycle stage in the chronic pain management market.

Collegium Pharmaceutical, Inc. COLL Nucynta ER AG — Product revenues, net

Other product segments

Belbuca

$52.65M+1.9%

Xtampza ER

$50.77M—

Jornay PM

$38.89M+36.3%

Nucynta IR

$26.08M-4.9%

Nucynta ER

$18.23M-7.4%

Symproic and other

$14.45M—

Symproic

$4.19M+49.0%

Nucynta IR AG

$1.26M—

Similar metrics at other companies

LNTHNeuraceq — Revenue

$35.44M—

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

OGNNuvaRing — Revenue

$24M+9.1%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

XER

XERSProduct revenue, net — Product revenue, net

$82.45M+42.6%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

Other financials

Income statement

See full

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Balance sheet

See full

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Cash flow

See full

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Valuation

See full

Market cap$1.15B+20.4%

Enterprise value$869.67M+2.5%

P/E15.4×-6.4×

P/S1.5×0.0×

Profitability

See full

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Returns & leverage

See full

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s nucynta er ag — product revenues, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s nucynta ER AG — product revenues, net?: Collegium Pharmaceutical, Inc. (COLL) reported nucynta ER AG — product revenues, net of $1.45M in Q1 2026.
What does nucynta ER AG — product revenues, net mean?: This metric represents the net revenue generated from the sale of the Nucynta ER product line, reflecting the total sales after accounting for returns, rebates, and other adjustments. It serves as a key indicator of the product's market adoption and commercial performance within the company's specialty pharmaceutical portfolio. Monitoring this revenue stream helps investors assess the product's contribution to overall top-line growth and its lifecycle stage in the chronic pain management market.